N6-methyladenosine (m6A) is the most prevalent modification in eukaryotic RNAs. The biological importance of m6A relies on m6A readers, which control mRNA fate and function. However, it remains unexplored whether additional regulatory subunits of m6A readers are involved in the m6A recognition on RNAs. Here we discover that the long noncoding RNA (lncRNA) LINC00266-1 encodes a 71-amino acid peptide. The peptide mainly interacts with the RNA-binding proteins, including the m6A reader IGF2BP1, and is thus named “RNA-binding regulatory peptide” (RBRP). RBRP binds to IGF2BP1 and strengthens m6A recognition by IGF2BP1 on RNAs, such as c-Myc mRNA, to increase the mRNA stability and expression of c-Myc, thereby promoting tumorigenesis. Cancer patients with RBRPhigh have a poor prognosis. Thus, the oncopeptide RBRP encoded by LINC00266-1 is a regulatory subunit of m6A readers and strengthens m6A recognition on the target RNAs by the m6A reader to exert its oncogenic functions.
N6-methyladenosine (m6A) is the most prevalent modification of eukaryotic RNAs. RNA m6A methylation is reversibly and dynamically regulated by the RNA methyltransferases (i.e., the m6A writers) METTL3 and METTL14, and demethylases (i.e., the m6A erasers) FTO and ALKBH51,2,3. The biological importance of RNA m6A modification relies on m6A-binding proteins (i.e., the m6A readers), which directly guide distinct biological functions1,2. A group of YT521-B homology (YTH) domain-containing proteins, including YTHDF1, YTHDF2, YTHDF3, YTHDC1, and YTHDC2, the IGF-2 mRNA-binding proteins, including IGF2BP1, IGF2BP2, and IGF2BP3, and the heterogeneous nuclear ribonucleoproteins hnRNPA2B1 and hnRNPC have been identified as m6A RNA readers that control mRNA fate by regulating mRNA stability, translation, splicing, structure, decay, and subcellular localization4,5,6,7,8. Recently, a handful of additional regulatory subunits of m6A methyltransferases, including WTAP, VIRMA, ZC3H13, HAKAI, and RBM15/15B, are found to play an important role in the installation of m6A on RNAs1,9,10,11,12. However, the regulatory subunits of m6A RNA readers and m6A demethylases remain unexplored.
Long noncoding RNAs (lncRNAs) comprise the largest proportion of mammalian noncoding transcripts. LncRNAs are defined as transcripts of more than 200 nucleotides that do not contain protein-coding open reading frames (ORFs). The ENCODE project demonstrates that the human genome contains more than 28,000 distinct lncRNA transcripts13. LncRNAs have been identified as significant factors in cells by regulating gene transcription (in cis or trans), chromatin remodeling, and mRNA splicing; producing endogenous small interfering RNAs (siRNAs) and microRNA precursors; changing protein localization; regulating protein activity; and organizing protein components14,15. The dysregulation of lncRNAs has been linked to the hallmarks of cancers and cancer patient survival time16,17,18. However, whether lncRNAs are involved in regulating the installation, removal or recognition of m6A on RNAs remains unexplored.
In this study, we discover that LINC00266-1, which was previously annotated as an lncRNA in Homo sapiens and whose functions are unknown, actually encodes a 71-amino acid (aa) peptide. The peptide mainly interacts with RNA-binding proteins, including the m6A reader IGF2BP1. Thus, we term the peptide “RNA-binding regulatory peptide” (RBRP). RBRP binds to the m6A reader IGF2BP1 and promotes the m6A recognition by IGF2BP1 on RNAs such as c-Myc mRNA to increase the c-Myc mRNA stability and level by enhancing the recruitment of the RNA stabilizers HuR, MATK3, and PABPC1. The RBRP oncopeptide, but not the lncRNA LINC00266-1 itself, promotes colorectal cancer (CRC) tumorigenesis by enhancing m6A recognition-dependent c-Myc mRNA stability. The LINC00266-1 lncRNA level and RBRP oncopeptide level are increased in cancer tissues and are highly metastatic cell sublines compared with their levels in the corresponding adjacent nontumor tissues and parent cell lines, respectively. Patients with CRC presenting with high RBRP oncopeptide levels exhibit more aggressive clinicopathological phenotypes and shorter survival times than patients presenting with low levels. Collectively, our findings reveal that an oncopeptide, RBRP, encoded by the uncharacterized lncRNA LINC00266-1, is an additional subunit of the m6A reader and regulates the m6A recognition by m6A readers on target RNAs and tumorigenesis.
Identification of lncRNAs with coding potential
An lncRNA with coding potential must bind to the ribosome. The ribosome-bound RNAs in CRC SW480 cells and the corresponding metastatic SW620 cells were separately sequenced. The identified lncRNAs were examined in this study. Three hundred and eighty-four differentially expressed ribosome-bound lncRNAs with a fold-change ≥1.2 were identified between SW480 and SW620 cells (Supplementary Data 1). The coding potential of these 384 ribosome-bound lncRNAs was further analyzed using the ORF Finder program from the NCBI tools. Fifty-five lncRNAs with coding potential that were differentially expressed between SW480 and SW620 cells were discovered (Supplementary Data 1).
The predicted peptide/protein-coding ORFs of the ten lncRNAs with coding potential, namely LINC00263, KTN1-AS1, ZNF205-AS1, LOC100126784, LINC00266-1, LINC00115, LOC286467 (FIRRE), FLJ20021, LOC728752, and LOC284581, were selected and individually fused to the N terminus of the start codon-mutated GFP vectors (GFPmut). Only the ORFs of the lncRNAs LINC00266-1 and FLJ20021 were able to be translated; the other eight lncRNAs did not have coding potential (Fig. 1a). The lncRNA LINC00266-1 was further investigated here and FLJ20021 will be investigated in other studies.
The lncRNA LINC00266-1 encodes an uncharacterized peptide, RBRP
The lncRNA LINC00266-1 was previously annotated as an intergenic lncRNA (lincRNA) in H. sapiens (NR_040415) and its functions are unknown. We observed a short 213-nucleotide ORF with the potential to encode a 71-aa peptide (Supplementary Fig. 1). We termed this peptide RBRP. Sequence comparisons did not identify homologs of LINC00266-1 or the RBRP peptide in any other species, and there were no matching proteins and known domains/motifs in RBRP, indicating that RBRP is an uncharacterized peptide.
We generated a series of Flag-fused constructs containing the ORF and the 5′-untranslated region (5′-UTR)-ORF of LINC00266-1 and ATG-mutated start codon constructs to confirm that the start codon of the predicted ORF of the lncRNA LINC00266-1 was active. Substantial expression of the RBRP-Flag fusion peptide was observed in LINC00266-1 ORF-Flag (ORF)- and 5′UTR-ORF-Flag (5′U)-transfected cells, whereas the mutation of the start codon ATG (5′UTR-ORFmut-Flag, MT) abolished the translation of the predicted ORF in LINC00266-1 (Fig. 1b, c).
We produced an antibody against the RBRP peptide to further detect and validate the RBRP peptide that was encoded by the LINC00266-1 ORF in cells. The specificity of the anti-RBRP antibodies against the RBRP peptide was validated (Supplementary Fig. 2a, b). The RBRP-Flag fusion peptides were further validated using anti-RBRP antibodies in LINC00266-1 ORF- and 5′UTR-ORF-transfected cells, whereas a mutation in the ATG start codon in the ORF of LINC00266-1 abolished the detection of the RBRP fusion peptide (Fig. 1b, c). Collectively, the RBRP fusion peptide was translated into cells.
Finally, the LINC00266-1 ORF-GFPmut fusion construct was transfected into HEK293T cells and the RBRP-GFP fusion peptide was immunoprecipitated using an anti-green fluorescent protein (GFP) antibody. Two unique peptide fragments in the RBRP peptide were identified using mass spectrometry (MS) (Fig. 1d). Collectively, these data indicate that LINC00266-1, which is previously annotated as a lncRNA, actually encodes a 71-aa peptide.
The RBRP peptide is naturally, endogenously expressed
We detected the cellular RBRP peptide using anti-RBRP antibodies to validate the presence and expression of the natural, endogenous RBRP peptide in cells and tissues. Our developed anti-RBRP antibodies specifically detected the naturally endogenously produced RBRP peptide (Supplementary Fig. 2c–e). The natural, endogenous RBRP peptide was validated in colorectal, breast, ovarian, and nasopharyngeal cancer cells (Fig. 2a, b). In addition, the RBRP peptide was confirmed to be naturally endogenously produced in five pairs of matched fresh primary CRC tissues and their corresponding adjacent nontumoral colorectal tissues (Fig. 2c). Finally, three unique peptide fragments in the natural, endogenous RBRP peptide were identified using MS analysis (Supplementary Fig. 3), further indicating that the natural, endogenous RBRP peptide was present in cancer tissues. Taken together, RBRP is naturally, endogenously, and widely expressed in various cells and tissues.
Levels of the LINC00266-1 lncRNA and RBRP peptide are increased in highly metastatic cancer cells and primary cancers
According to our ribosome-bound RNA-sequencing data, LINC00266-1 expression was upregulated in CRC SW620 cells compared with the expression in SW480 cells. We further confirmed that LINC00266-1 lncRNA expression was upregulated in highly metastatic colorectal (SW620 and HCT-116high), ovarian (SK-OV-3high and OVCAR-3high), nasopharyngeal (S18), and breast (MDA-MB-231high) cancer cell sublines compared with the expression in their parental cell lines (Supplementary Fig. 4a, b). The levels of the LINC00266-1 lncRNA were also increased in five pairs of matched freshly frozen primary CRC tissues and their corresponding adjacent nontumoral colorectal tissues (Supplementary Fig. 4c, d). Unfortunately, no LINC00266-1 expression data were obtained from the publicly accessible datasets The Cancer Genome Atlas and Oncomine.
Similar to LINC00266-1 lncRNA levels, RBRP levels were also increased in highly metastatic colorectal, ovarian, nasopharyngeal, and breast cancer cell sublines compared with the levels in their parental cell lines, and the levels were also increased in the primary CRC tissues compared with the levels in the corresponding nontumoral colorectal tissues (Fig. 2b, c). Furthermore, an extensive tissue microarray analysis of 90 pairs of matched CRC tissues and corresponding nontumor samples of colorectal tissues was performed using immunohistochemistry (IHC) with anti-RBRP antibodies (Fig. 2d). Similar to the results in Fig. 2c, increased RBRP levels were observed in CRC tissues compared with the levels in adjacent nontumor samples of colorectal tissues (Fig. 2e). Taken together, the levels of the LINC00266-1 lncRNA and RBRP peptide were markedly increased in highly metastatic cancer cell sublines and primary cancer tissues compared with the levels in their corresponding parental cell lines and nontumoral tissues, respectively, suggesting that the lncRNA LINC00266-1 and its encoded peptide RBRP play important roles in tumorigenesis.
RBRP peptidehigh serves as an independent prognostic factor for patients with CRC
The correlations between the RBRP levels and the clinicopathological features of patients with cancer were investigated in 90 pairs of matched CRC and corresponding nontumor colorectal tissue samples. Increased RBRP levels positively correlated with advanced clinical stages of CRC (p = 0.027; Supplementary Table 1). Kaplan–Meier survival analyses revealed that patients with CRC who presented with higher RBRP levels had an increased risk of cancer-related death than patients who presented with lower RBRP levels (Fig. 2f, g; p = 0.000007, log-rank test). The mean overall survival of patients with CRC and RBRPhigh was 45.3 months, whereas the value for patients with CRC and RBRPlow was 67.1 months. Furthermore, a multivariate Cox regression analysis indicated that RBRPhigh was an independent prognostic factor for poor survival in patients with CRC (hazard ratio = 8.26, 95% confidence interval = 2.84–24.02, p = 0.000; Supplementary Table 2). Collectively, our results reveal a significant correlation between a high RBRP level and a poor prognosis for patients with CRC, and the RBRP peptide serves as an independent prognostic factor for patients with CRC.
Knockdown of LINC00266-1 inhibits tumorigenesis
We silenced LINC00266-1 expression using two anti-LINC00266-1 siRNAs in HCT-116 and SW620 cells to investigate the functions of LINC00266-1 in CRC (Supplementary Fig. 2c–e). Knockdown of LINC00266-1 inhibited HCT-116 and SW620 CRC cell proliferation, colony formation, migration, and invasion (Supplementary Fig. 5a–c). Thus, the lncRNA LINC00266-1 is a driver of tumorigenesis.
The LINC00266-1-encoded RBRP peptide, but not the lncRNA LINC00266-1 itself, promotes tumorigenesis
We used the lentivirus expressing the LINC00266-1 short hairpin RNA (shRNA), which targets the 3′-UTR of the LINC00266-1 ORF, to stably knock down LINC00266-1 expression. Two CRC cell lines, HCT-116 and SW480, were constructed with the stable knockdown of LINC00266-1. In these cells, we restored the expression of ORF, 5′U, or MT, which confer resistance to shRNAs against LINC00266-1 (Fig. 3a). Knockdown of LINC00266-1 resulted in significant decreases in cell growth, colony formation, migration, and invasion, whereas these alterations were restored to the control level after the addition of ORF expression, but not LINC00266-1 MT expression (Fig. 3b–d), indicating that the RBRP peptide, but not the lncRNA LINC00266-1 itself, promotes tumorigenesis.
In addition, we transfected the LINC00266-1 ORF (ORF), 5′UTR-ORF (5′U), and 5′UTR-ORFmut (mut) Flag fusion constructs into two CRC cell lines to analyze the effects of the LINC00266-1-encoded RBRP peptide and the lncRNA LINC00266-1 itself on cancer progression. The LINC00266-1 ORF and 5′UTR-ORF constructs, both of which produce the RBRP peptide, promoted CRC cell proliferation, colony formation, migration, and invasion (Supplementary Fig. 5d–f). However, the LINC00266-1 5′UTR-ORFmut constructs, which do not encode the RBRP peptide and function as lncRNAs, did not alter cancer cell proliferation, colony formation, migration, or invasion.
The in vivo growth of xenografts derived from cancer cells stably expressing ORF and 5′U was significantly increased, whereas ectopic stable expression of LINC00266-1 MT constructs did not significantly alter xenograft tumor growth (Fig. 3e). In addition, larger metastatic nodules were developed in mice after tail vein injections with luciferase (Luc)-tagged cancer cells stably expressing ORF or 5′U than those in mice injected with the negative control (NC) cells; however, the injection with cells stably expressing LINC00266-1 MT did not significantly alter the metastatic nodules developed in mice (Fig. 3f, g). Collectively, the RBRP peptide produced by the lncRNA LINC00266-1, rather than the LINC00266-1 lncRNA itself, promotes tumorigenesis and metastasis in vitro and in vivo, and the RBRP peptide plays oncogenic roles.
RBRP interacts with the RNA m6A reader IGF2BP1
RBRP is an uncharacterized peptide with a lack of species conservation and homology to other proteins and domains/motifs. We identified the proteins that interact with RBRP using MS to elucidate the mechanism by which RBRP promotes tumorigenesis. One hundred and seven potential interactors with RBRP were here identified by interactomics assay (Fig. 4a and Supplementary Data 2). A gene annotation assay showed that 76 of these 107 proteins belong to the RNA-binding proteins. Thus, we termed the LINC00266-1-encoded peptide RBRP. The RNA-binding protein, RNA m6A reader IGF2BP1, was particularly interesting, because the protein score of IGF2BP1 was TOP5 in the identified RBRP interactors, RNA m6A modification play an important role in the hallmark of cancer, and IGF2BP1 regulates the level of an important oncogene c-Myc and tumorigenesis6,19,20, consistent with the oncogenic roles of RBRP in tumorigenesis. Therefore, we here select IGF2BP1 for further investigation. We further confirmed that IGF2BP1 was in RBRP coimmunoprecipitated (co-IPed) complexes, and that RBRP was in IGF2BP1 co-IPed complexes, indicating that RBRP bound to IGF2BP1 (Fig. 4b). Given that IGF2BP1 binds to m6A-modified RNA, we further investigated whether the interaction of RBRP with IGF2BP1 depends on RNA. We found that RBRP still interacted with IGF2BP1 in the presence of RNase A (Fig. 4c), indicating that the binding of RBRP to IGF2BP1 was RNA independent.
The IGF2BP1 protein consists of two N-terminal RNA recognition domains (RRM1 and RRM2) and four C-terminal heterogeneous ribonucleoprotein (hnRNP) K homology (KH) domains (KH1–4)21. We generated IGF2BP1-HA truncated fusion constructs (Fig. 4d) and coexpressed these constructs in HEK293T cells with ORF to investigate which domains bind to RBRP. We found that RBRP bound to the KH3–4 di-domain of IGF2BP1 (Fig. 4e, f). A previous study reported that the GxxG motif in the KH3–4 di-domain is indispensable for m6A recognition and binding6. We found that mutating GxxG to GEEG in the KH3–4 di-domain completely abolished the interaction of RBRP with IGF2BP1 (Fig. 4g, h).
The domain or residue of RBRP binding to IGF2BP1 was further investigated. The mutation of G19, but not G63, to A destroyed the binding of RBRP to IGF2BP1 (Fig. 4i, j), suggesting that the G19 residue in RBRP is essential for IGF2BP1 binding. Taken together, RBRP binds to the RNA m6A reader IGF2BP1.
RBRP promotes tumorigenesis through IGF2BP1
As expected, silencing of IGF2BP1 suppressed CRC cell proliferation, colony formation, migration, and invasion in HCT-116 and SW480 CRC cells (Supplementary Fig. 6), similar to the cancer phenotypes induced by RBRP knockdown. To investigate whether RBRP promotes tumorigenesis through IGF2BP1, we cotransfected cells with ORF (encoding RBRP) or ORFmut-Flag (MUT) (as LNC00266-1 lncRNA) with anti-IGF2BP1 siRNA (Supplementary Fig. 7a). The increases in cell proliferation, colony formation, and migration and invasion induced by RBRP overexpression were completely blocked by IGF2BP1 knockdown (Supplementary Fig. 7b–d), indicating that RBRP promotes tumorigenesis through IGF2BP1.
RBRP strengthens the m6A recognition by the m6A reader IGF2BP1 on RNAs
A previous study showed that IGF2BP1 is an RNA m6A reader6. We used m6A-methylated single-stranded RNA oligos with the consensus sequence GG(m6A)CU (ss-m6A) to investigate the influence of RBRP on m6A recognition by IGF2BP1 on RNAs. RBRP, but not the LINC00266-1 lncRNA itself, enhanced the binding of IGF2BP1 to m6A-RNA oligos, whereas RBRP did not change the unbinding of IGF2BP1 to the m6A-unmethylated control RNA (ss-A) (Supplementary Fig. 8a). The GxxG motifs in the IGF2BP1 KH3–4 di-domain are essential for m6A recognition and binding. RBRP did not increase the binding of IGF2BP1 to m6A-RNA when GxxG was mutated to GEEG (GxxGΔ) (Supplementary Fig. 8b). Moreover, the mutation of G19 to A19 in RBRP, which did not bind to the m6A reader IGF2BP1, completely destroyed the effects of RBRP on increasing the binding of endogenous IGF2BP1 to m6A-methylated RNA oligos (Supplementary Fig. 8c). Similar to endogenous RBRP peptides, a recombinant RBRP oncopeptide increased the binding of the recombinant IGF2BP1 protein to m6A-methylated RNA oligos, whereas a recombinant G19A-mutated RBRP oncopeptide did not (Supplementary Fig. 8d). Collectively, RBRP enhances the m6A recognition by IGF2BP1 on RNAs.
Previous studies have shown that IGF2BP1 stabilizes the c-Myc mRNA by associating with the coding region instability determinant (CRD)20 and the m6A-seq assay showed that the CRD was marked with m6A peaks6. C-Myc is one of the most important oncogenes, consistent with the oncogenic roles of RBRP in tumorigenesis. Thus, c-Myc is particularly interesting and we select c-Myc for a systematic investigation. An ~250 nt CRD in the 3′-terminus of the c-Myc mRNA coding region has been reported to be critical for IGF2BP1 binding and m6A-seq showed that the CRD region has a high abundance of m6A modifications6. Two CRD RNA oligos containing the consensus sequence GG(m6A)CU (ss-m6A) (CRD1 and CRD2) were synthesized according to the previous study6. RBRP, but not the LINC00266-1 lncRNA itself, increased the binding of endogenous IGF2BP1 to m6A-methylated c-Myc CRD RNA oligos, but did not change the unbinding of IGF2BP1 to m6A-unmethylated c-Myc CRD RNA oligos (Fig. 5a). The RNA immunoprecipitation (RIP)-quantitative PCR (qPCR) assay further confirmed that RBRP, but not the LINC00266-1 lncRNA, increased the binding of endogenous IGF2BP1 to c-Myc CRD RNA in cells (Fig. 5b). Similar to endogenous RBRP peptides, a recombinant RBRP oncopeptide increased the binding of the recombinant IGF2BP1 protein to the m6A-methylated c-Myc mRNA CDR oligos (Fig. 5f). Moreover, IGF2BP1-bound RNAs had more RNA m6A modification abundance when RBRP, but not the LINC00266-1 lncRNA itself, was overexpressed in cells (Fig. 5c). RBRP did not increase the recognition by endogenous IGF2BP1 for the m6A-modified mRNA CRD of c-Myc when the GxxG motifs in the IGF2BP1 KH3–4 di-domain were mutated to GEEG (GxxGΔ) (Supplementary Fig. 9a, b). These data indicate that RBRP increases the binding of IGF2BP1 to the m6A-modified mRNA CRD of c-Myc.
Furthermore, we found that the RBRP G19A mutant, which does not bind to IGF2BP1, did not increase the binding of endogenous IGF2BP1 to m6A-methylated c-Myc CRD RNA oligos (Fig. 5d). An RIP-qPCR assay also demonstrated that the RBRP G19A mutant did not enhance the binding of endogenous IGF2BP1 to c-Myc CRD RNA in cells (Fig. 5e). In addition, a recombinant G19A-mutated RBRP oncopeptide did not increase the binding of the recombinant IGF2BP1 protein to the m6A-methylated c-Myc mRNA CDR oligos (Fig. 5f). IGF2BP1-bound RNAs in wild-type (WT) RBRP-expressed cells had more RNA m6A modification abundance than those in RBRP G19A mutant-expressed cells (Fig. 5g). These results indicate that RBRP increases the binding of IGF2BP1 to m6A-modified c-Myc CRD mRNA by its G19 residue.
As shown above, RBRP did not increase the in vitro binding of IGF2BP1 to m6A-unmethylated RNA oligos. An RIP-qPCR assay further demonstrated that the enhancement of the binding of endogenous IGF2BP1 to the c-Myc CRD RNA induced by RBRP overexpression was significantly impaired when the cellular RNA m6A level was decreased by silencing the expression of the m6A writer METTL14 (Fig. 5h and Supplementary Fig. 9c). Moreover, we generated a c-Myc CRD mutant (CRDmut) in which A was mutated to U within six m6A consensus sequences in c-Myc CRD. RIP-qPCR and m6A-PCR assays demonstrated that RBRP did not increase the recognition of IGF2BP1 to m6A-modified c-Myc CRD mRNA when A was mutated to U within the six m6A consensus sequences in c-Myc CRD in cells (Fig. 5i and Supplementary Fig. 9d), indicating that RBRP increases the recognition and binding of IGF2BP1 to c-Myc CRD mRNA in an m6A-dependent manner. Taken together, RBRP, but not the lncRNA LINC00266-1 itself, strengthened the m6A recognition and binding of the m6A reader IGF2BP1 on RNAs, such as c-Myc mRNA.
RBRP increases c-Myc mRNA stability by strengthening the m6A recognition by IGF2BP1 on c-Myc mRNA
A previous study showed that IGF2BP proteins enhance the stability of target mRNAs in an m6A-dependent manner6. Thus, we further investigated the influences of RBRP on c-Myc mRNA stability. RBRP, not the lncRNA LINC00266-1 itself, increases the stability of c-Myc mRNA, as well as the c-Myc mRNA and protein levels (Fig. 6a–c). The silencing of IGF2BP1 completely blocked the enhancement of c-Myc mRNA stability induced by RBRP overexpression (Fig. 6d), indicating that RBRP increased c-Myc mRNA stability mainly through the m6A reader IGF2BP1.
Furthermore, the enhancement of the stability of c-Myc mRNA induced by RBRP overexpression was abolished when the m6A writer METTL14 was knocked down (Fig. 6e), suggesting that RBRP-mediated c-Myc mRNA stability is dependent on mRNA m6A modification. The A to U mutations within the six m6A consensus sites in c-Myc CRD mRNA significantly abrogated the enhanced stability of c-Myc mRNA and the increased c-Myc mRNA and protein levels induced by RBRP overexpression in cells (Fig. 6f–h). These results show that RBRP increases c-Myc mRNA stability in a c-Myc CRD mRNA m6A-dependent manner.
We next sought to determine whether the RBRP oncopeptide level and c-Myc level are correlated in clinical samples. The c-Myc mRNA and protein levels in CRC tissues were higher than those in the corresponding nontumoral colorectal tissues (Fig. 6i, j). The c-Myc levels were positively correlated with RBRP oncopeptide levels in clinical sample tissues (R2 = 0.5921, p = 0.0093) (Fig. 6k).
The RNA stabilizers HuR, MATR3, and PABPC1 have been identified to regulate the stability of target mRNAs22,23,24. We demonstrated that RBRP increased the interaction of IGF2BP1 with the RNA stabilizers HuR, MATR3, and PABPC1 in an RNA-independent manner, whereas the mutation of G19A in RBRP, which did not bind to IGF2BP1, did not increase the binding of IGF2BP1 to these RNA stabilizers (Supplementary Fig. 10a, b). Moreover, RBRP enhanced the binding of these RNA stabilizers to m6A-RNA probes and m6A-methylated c-Myc CRD RNAs but did not promote the binding of these RNA stabilizers to m6A-unmethylated RNA probes and m6A-unmethylated c-Myc CRD RNAs (Supplementary Fig. 10c, d). However, the RBRP G19A mutant, which does not bind to IGF2BP1, did not increase the binding of these RNA stabilizers to m6A-methylated c-Myc CRD RNAs (Supplementary Fig. 10e). Thus, RBRP strengthens the recruitment of the RNA stabilizers HuR, MATR3, and PABPC1 to m6A-c-Myc CRD RNAs, to promote the stability of c-Myc mRNA and upregulate the c-Myc levels. Collectively, our results indicated that RBRP increases c-Myc mRNA stability by strengthening the m6A recognition by IGF2BP1 on c-Myc CRD mRNA and the recruitment of RNA stabilizers to m6A-methylated-c-Myc CRD mRNA.
RBRP promotes tumorigenesis through c-Myc
C-Myc is a key, well-known oncogene. We next investigated whether RBRP promoted tumorigenesis through c-Myc, because RBRP drives m6A recognition-dependent c-Myc mRNA stability. Either the ORF (encoding the RBRP oncopeptide) or MT (MUT) (LNC00266-1 lncRNA) construct was cotransfected together with anti-c-Myc siRNAs into cells (Supplementary Fig. 11a). The increases in cell proliferation, colony formation, and migration and invasion induced by RBRP overexpression were completely blocked by c-Myc knockdown (Supplementary Fig. 11b–d). Thus, RBRP promotes tumorigenesis mainly through c-Myc.
RBRP exerts its oncogenic roles by binding to IGF2BP1
As shown above, RBRP increases the m6A recognition by IGF2BP1 on RNAs and promotes c-Myc mRNA stability and tumorigenesis through IGF2BP1. Therefore, we further examined whether RBRP promotes tumorigenesis and c-Myc mRNA stability in an IGF2BP1-binding-dependent manner. The expression of the WT RBRP or the IGF2BP1-binding-defective mutant RBRP G19A, which is resistant to the LINC00266-1 shRNA that targeted the 3′-UTR of the RBRP ORF, was restored in CRC cells with stable knockdown of LINC00266-1. Knockdown of LINC00266-1 significantly decreased the c-Myc mRNA stability and level, cell growth, colony formation, migration, and invasion, whereas these alterations were restored to the control levels in cells cotransfected with WT RBRP but not with the IGF2BP1-binding-defective mutant RBRP G19A (Fig. 7), indicating that RBRP promotes tumorigenesis and c-Myc mRNA stability by binding to IGF2BP1.
m6A RNA modifications play an important role in posttranscriptional gene regulation, development, and diseases, such as cancers1,2. m6A RNA modifications exert their biological importance through m6A readers. However, how these m6A readers recognize their target transcripts remains largely unknown. In this study, we found that an uncharacterized oncopeptide RBRP encoded by the previously annotated, uncharacterized lncRNA LINC00266-1 is significantly upregulated in cancers and strengthens the recognition and binding of the m6A reader IGF2BP1 to target mRNAs, such as c-Myc mRNA, to increase the stability and level of c-Myc mRNA, thereby promoting tumorigenesis.
The effectors in the m6A RNA pathway include the writers METTL3 and METTL14; the erasers FTO and ALKBH5; and the readers YTHDF1-3, YTHDC1-2, IGF2BPs, and hnRNPs1,2,4,5,6,7,8. The m6A RNA modification is installed mainly through METTL3 and METTL14, which are the catalytic subunit and an essential component to facilitate RNA binding, respectively3. In addition to METTL3 and METTL14, recent studies have further shown that a handful of additional regulatory subunits, including WTAP, VIRMA, ZC3H13, HAKAI, and RBM15/15B, also play an important role in the installation of m6A on RNA9,10,11,12. However, the additional regulatory subunits of RNA m6A readers and m6A demethylases are not reported. In this study, our findings indicate that m6A readers also contain additional regulatory subunits. Here we found that the oncopeptide RBRP encoded by the lncRNA LINC00266-1 is a regulatory subunit of the RNA m6A reader IGF2BP1 and regulates the m6A recognition by IGF2BP1 on target RNAs. Our findings unveil an additional regulatory layer for the m6A pathway and m6A recognition.
m6A RNA methylation is emerging as a pathway affecting the hallmarks in a variety of cancers2. m6A RNA writers, erasers, and readers were identified to be dysregulated in several cancers and were found to regulate cancer initiation, proliferation, stemness, metastasis, resistance to chemo-/radiotherapy, and tumorigenesis in an m6A-dependent manner25,26,27,28,29,30. Although the regulatory subunits of the m6A writers WTAP, VIRMA, ZC3H13, and HAKAI have been reported to be associated with cancers31,32,33, whether their functional roles in cancers are dependent on m6A modification is not reported. In this study, we found that the regulatory subunit RBRP of the m6A reader promotes cancer cell proliferation, colony formation, tumorigenesis, and metastasis in an m6A- and m6A reader-dependent manner. RBRP strengthens the m6A recognition on target mRNAs, such as oncogene c-Myc mRNAs by IGF2BP1 to increase the stability and level of the c-Myc mRNA, thereby promoting tumorigenesis. The enhancement effects of RBRP on m6A recognition, mRNA stability, and tumorigenesis are impaired when the m6A modification is absent from cellular c-Myc CRD mRNA. Our results indicate that, in addition to the aberrant m6A modification being closely associated with cancer, the aberrant m6A recognition mediated by the regulatory subunit of the m6A reader is also closely associated with cancer.
The RBRP oncopeptide is an uncharacterized peptide that is encoded by the previously annotated lncRNA LINC00266-1 with unknown functions. The interactomics and MS analyses identified that a total of 107 proteins interacted with the LINC00266-1-encoded peptide. A gene annotation assay showed that 76 of these 107 proteins belong to the RNA-binding proteins. Thus, we termed the LINC00266-1-encoded peptide RBRP. The RBRP peptide, not the lncRNA LINC00266-1 itself, exerts its oncogenic functions to promote cancer cell proliferation, colony formation, migration, and invasion in vitro and to promote tumorigenesis and metastasis in vivo. Therefore, RBRP is further termed an oncopeptide. The inhibition of RBRP can significantly suppress cancer cell proliferation, colony formation, migration, and invasion. m6A RNA writers, erasers, and readers have been suggested to be anticancer therapeutic targets1,34. Our results showed that the regulatory subunit RBRP oncopeptide of the m6A reader may be a potential cancer prognosis biomarker and therapeutic target.
In addition to the role of RBRP in the m6A recognition by interacting with IGF2BP1, the gene annotation assay demonstrated that RBRP interactors mainly involve in the regulation of RNA splicing and many splicing regulators interact with RBPR including ten hnRNP family proteins, seven splicing factors, and two small nuclear ribonucleoproteins, most of which have been reported to be involved in the regulation of the hallmarks of cancer17,35,36, suggesting that RBRP may also regulate pre-mRNA splicing to regulate tumorigenesis and cancer progression. Therefore, the interactions of RBRP with other interactors will be valuable to explore in next step.
To date, more than 28,000 lncRNA transcripts have been identified in the human genome. LncRNAs are emerging as important regulatory molecules of gene expression and have been functionally implicated in the regulation of multiple cellular processes as RNA molecules. The dysregulation of lncRNAs contributes to various cancer hallmarks16,17,18. However, until now, no lncRNA has been reported to participate in the installation, removal, or recognition of m6A on RNAs. In our present study, our findings reveal that the lncRNA LINC00266-1 participates in the m6A recognition by m6A readers and the lncRNA LINC00266-1 exerts its m6A recognition regulation by encoding an oncopeptide instead of an RNA molecule. Our and previous studies showed that a limited number of lncRNAs and circRNAs could encode proteins/peptides to regulate tumorigenesis37,38,39,40. Our findings further confirmed that some peptides are hidden in some previously annotated lncRNAs. Our report enriches and broadens the breadth and diversity of noncoding RNA functions and mechanisms in the m6A RNA pathway and in tumorigenesis.
In summary, a previously annotated lncRNA, LINC00266-1, actually encodes an uncharacterized peptide, RBRP, which exhibits oncogenic roles in tumorigenesis; this finding highlights the therapeutic potential of targeting RBRP in cancers. The RBRP oncopeptide, as an additional regulatory subunit of m6A readers, strengthens the m6A recognition on RNAs, such as c-Myc mRNA, by the m6A reader IGF2BP1 to increase c-Myc mRNA stability and expression. Our study uncovers a connection between an lncRNA and its encoded peptide and the m6A RNA pathway.
Cell culture and tissue samples
SW480, SW620, HCT-116, MBA-MD-231, SK-OV-3, OVAR-3, HeLa, and HEK293T cell lines were purchased from the American Type Culture Collection and cultured under standard conditions. HCT-116high, MDA-MB-231high, OVCAR-3high, and SK-OV-3high cell sublines with increased metastatic abilities were previously established by our group17,41. S18 and S26 cell lines were kindly provided as described in our previous study17. Cells were regularly monitored for mycoplasma contamination.
Matched fresh frozen primary CRC tissues and their corresponding adjacent nontumor samples of colorectal tissues were collected from patients with CRC at Sun Yat-sen University Cancer Center. These cases were selected based on a clear pathological diagnosis, and the patients were not preoperatively treated with anticancer agents. The collection of these tissue samples was approved by the Internal Review and Ethics Boards at the Third Affiliated Hospital of Guangzhou Medicine University. Informed consent was obtained from each patient.
Tissue microarray chips containing 90 pairs of matched CRC tissue samples, their corresponding adjacent nontumor colorectal tissue samples, and the related clinicopathological data were purchased from Shanghai OUTDO Biotech Co., Ltd (Shanghai).
Anti-RBRP antibody production
The epitope peptide was synthesized and anti-RBRP antibodies were produced by GL Biochem (Shanghai), Ltd. Briefly, a KLH-coupled peptide, Cys-TDTKKDKHPDPY (CY-13), was synthesized and polyclonal antibodies against RBRP were obtained from inoculated rabbits. Antibodies were further purified using affinity chromatography on columns containing the corresponding epitope peptides.
The LINC00266-1 and other lncRNA ORF-GFPmut, ORF, 5′U, and MT, IGF2BP1-HA, IGF2BP1-Flag, c-Myc-Flag plasmids were generated as previously described17. The IGF2BP1-HA MUT1, MUT2, MUT3, MUT4, GxxGΔ (GxxG mutates to GEEG) mutants, RBRP-Flag G19A, G63A, and G19A/G63A mutants, c-Myc CRDmut mutant, and synonymous mutated IGF2BP1 and c-Myc mutants were generated using a Mut Express II Fast Mutagenesis Kit V2 (Vazyme, China). The ORF, 5′U, and MT sequences were provided in Supplementary Table 3.
siRNAs (60 nM) against LINC00266-1, IGF2BP1, or c-Myc genes or NC siRNA (GenePharma) were transfected into the cells with RNAiMAX (Invitrogen) for 48 h (unless otherwise stated). The plasmids together with 50 nM siRNAs were cotransfected using Lipofectamine 2000 (Invitrogen) for 48 h (unless otherwise stated). The siRNA sequences were provided in Supplementary Table 3.
HeLa cells were transfected with LINC00266-1 and other lncRNA ORF-GFPmut vectors, and GFP fluorescence was directly visualized and recorded. HeLa cells were transfected with the indicated plasmids or the indicated siRNAs for 24 h, and these cells were then plated and cultured on glass cover slips for 24 h. These cells were fixed with 4% paraformaldehyde, permeabilized with 0.1% Triton X-100, and incubated with anti-RBRP or anti-Flag antibodies at 4 °C overnight. Subsequently, these cells were treated with the corresponding Alexa Fluor 488- or Cy3-conjugated secondary IgG antibodies (1:1000), and cellular nuclei were stained with DAPI. The images were obtained by laser scanning confocal microscopy.
Whole-cell lysates and tissue lysates were prepared, and the protein concentrations were determined as previously described42. Whole-cell lysates and tissue lysates were separated using 10–12.5% Tris-SDS-polyacrylamide gel electrophoresis (PAGE) and then electroblotted onto a polyvinylidene fluoride (PVDF) membrane. The indicated proteins were detected using anti-RBRP (our developed, 1:500), Flag (M185-3L, MBL, RRID: AB_11123930, 1:2000), HA (561, MBL, RRID: AB_591839, 1:2000), GFP (50430-2-AP, Proteintech, RRID: AB_11042881, 1:1000), IGF2BP1 (8482, CST, 1:1500), c-Myc (13987, CST, RRID: AB_11179079, 1:1000), m6A (ABE572, Merck Millipore, 1:2000), HuR (11910-1-AP, Proteintech, RRID: AB_11182183, 1:2000), PABPC1 (10970-1-AP, Proteintech, RRID: AB_10596918, 1:2000), MATR3 (12202-2-AP, Proteintech, RRID: AB_2281752, 1:2000), and β-actin (60008-1-Ig, Proteintech, RRID: AB_2289225, 1:4000) antibodies.
Tricine-SDS-PAGE and low-molecular-weight peptide detection
Whole-cell lysates and tissue lysates were prepared and the protein concentrations were determined as previously described42. Whole-cell lysates and tissue lysates were separated on 16% Tricine-SDS-PAGE gels as previously described17,43 and then electroblotted onto a PVDF membrane. Western blotting was performed using anti-Flag (M185-3L, MBL, RRID: AB_11123930) or anti-RBRP (1:500) antibodies to detect RBRP oncopeptide.
RT-PCR and qRT-PCR
Total RNA or RIP RNA was extracted using TRIzol total RNA isolation reagent (Invitrogen). LINC00266-1 lncRNA, IGF2BP1, METLL14, c-Myc, c-Myc CRD, and GAPDH mRNA levels were determined using reverse transcriptase PCR (RT-PCR) or quantitative RT-PCR (qRT-PCR). The sequences of the RT-PCR and qRT-PCR primers were provided in Supplementary Table 3.
IHC assays were performed as previously described using anti-RBRP antibodies44. IHC assays were performed on colon cancer tissue microarray chips with anti-RBRP antibody (1:600). All IHC results were assessed by two independent pathologists blinded to both the sample origins and the subject outcomes. RBRP oncopeptide level scores were evaluated using a previously described semiquantitative German scoring system with the percentage of positive cells and the staining intensity. Scores of 0–3 indicated low RBRP micropeptide levels (low) in cancer tissues, whereas scores of 4–7 indicated high RBRP micropeptide levels (high) in cancer tissues.
Cell proliferation assay
Cell proliferation assays were performed as previously described17,41. Briefly, cells were transfected with the indicated siRNAs and/or plasmids for 12 h. These cells were suspended, and 1 × 104 cells were then plated in 96-well culture plates and cultured in culture medium supplemented with 10% fetal bovine serum (FBS). The cell number was counted at 24, 48, 72, 96, and 120 h.
Colony formation assays
Cell proliferation assays were performed as previously described17,41. Briefly, cells were transfected with the indicated siRNAs and/or plasmids for 12 h. Then, 250 cells were plated in six-well culture plates and cultured in medium supplemented with 10% FBS. These cells were then fixed with methanol and stained with crystal violet solution. The colony numbers were counted under a microscope (n = 3).
Migration and invasion assays
In vitro migration and invasion assays were performed using Transwell chambers as previously described45. Cells were transfected with the indicated siRNAs or/and plasmids. A total of 1 × 105 cells in 100 μL cell suspensions with 0.05% FBS was added to the upper transwell chambers for the migration assay (8.0 μM pore size, BD) or the upper transwell chambers coated with Matrigel for the invasion assay, and medium with 10% FBS was added to the bottom chamber. Migrated and invasive cells were stained with 5% crystal violet. Images were obtained from each membrane, and migrated and invasive cells were counted under a microscope.
Construction of cell lines with stable expression
The HCT-116-Luc cell line stably expressing Luc was previously established by our group17. HCT-116-Luc cells were further infected with lentiviruses expressing the indicated LINC00266-1 constructs and selected using puromycin. The ectopic expression of the RBRP-Flag fusion protein was validated by western blotting. HCT-116 cell lines stably expressing LINC00266-1-ORF-Flag (HCT-116-Luc-LINC00266-1-ORF-Flag), LINC00266-1-5′U (HCT-116-Luc- LINC00266-1-5’UTR-ORF-Flag), or LINC00266-1-MT (HCT-116-Luc- LINC00266-1-MT) were established.
HCT-116 cells were infected with lentiviruses expressing LINC00266-1 shRNA targeted to the 3′-UTR region of LINC00266-1 ORF and selected using puromycin. HCT-116 cell lines stably expressing LINC00266-1 shRNA were established.
Male BALB/c nude mice (3–4 weeks old) were purchased from Charles River Laboratories in China (Beijing). An in vivo tumorigenesis assay was performed as previously described17,41. Briefly, 1 × 106 HCT-116-Luc-LINC00266-1-ORF-Flag, HCT-116-Luc- LINC00266-1-5′U, or HCT-116-Luc-LINC00266-1-MT cells were subcutaneously injected into the dorsal flanks of each BALB/c nude mouse (n = 6). After 3 weeks, the mice were killed and the tumors were dissected and weighed.
Male NOD-SCID mice (3–4 weeks old) were obtained from Charles River Laboratories in China. An in vivo metastasis assay was performed using previously described methods17,41. Briefly, NOD-SCID mice in each experimental group were injected with 2 × 106 HCT-116-Luc-LINC00266-1-ORF-Flag, HCT-116-Luc-LINC00266-1-5′U, or HCT-116-Luc-LINC00266-1-MT cells through the tail vein (n = 5). The metastatic foci were visualized 9 weeks after implantation using an IVIS 200 Imaging System (Xenogen).
The mice used in these experiments were bred and maintained under defined conditions at the Animal Experiment Center of the College of Medicine (SPF-grade facility), Jinan University, in which ambient temperature and humidity is 22 ± 2°C and 40–70%, respectively. The animal experiments were approved by the Laboratory Animal Ethics Committee of The Third Affiliated Hospital of Guangzhou Medicine University and Jinan University and conformed to the legal mandates and national guidelines for the care and maintenance of laboratory animals.
Cells were transfected with the indicated plasmids. Whole-cell lysates from cells were prepared as previously reported42. Coimmunoprecipitation assay (Co-IP) was performed using anti-Flag or anti-HA antibodies, and the immune complexes were captured on Protein A/G agarose beads (Santa Cruz). The co-IPed complexes were separated. The gels were stained with silver for MS assay or used for western blotting assay with the indicated antibodies. For the MS assay, three independent experiments were performed; the differential gel bands and their corresponding negative gel bands were excised and were in-gel-digested with trypsin.
For identification of exogenous RBRP peptide, the LINC00266-1 ORF-GFPmut plasmid was transfected into HeLa cells, the RBRP-GFP fusion peptide was immunoprecipitated using anti-GFP antibody, the immunoprecipitated RBRP-GFP was separated by SDS-PAGE and stained with silver, and the RBRP-GFP gel band was cut out and in-gel-digested with trypsin. For identification of endogenous RBRP peptide, the total proteins from tumor tissues were separated by tricine-SDS-PAGE and stained with silver. The gel bands with about 8 kDa were cut out and in-gel-digested with trypsin.
Protein identification was performed by MS as previously described17. MS assay was performed by Wininnovate Bio., Shenzhen. In brief, the extracted peptide mixtures, which were dissolved in buffer containing 0.1% formic acid and 2% acetonitrile (AcN), were eluted with a 5–40% gradient (0.1% formic acid and 95% AcN) and analyzed using nano-liquid chromatography–MS/MS AB SCIEX TripleTOF 5600, USA). Information-dependent acquisition mass spectrum techniques were used to acquire tandem MS data using a ion spray voltage of 2.4 kV, a air curtain pressure of 35 PSI, a atomizing pressure of 12 PSI, and an interface heating temperature of 150 °C. For an information dependent acquisition, survey scans were acquired in 250 ms and a maximum of 40 product ion scans (60 ms) were collected. Only the spectra with a charge state of two to four were selected to induce fragmentation by Collision-induced dissociation. A cycle time was set to 2.5 s. Dynamic exclusion was set to 16 s.
The WIFF RAW files were converted into peaklist files using Protein Pilot Software v4.5 (AB SCIEX). For the identification of RBRP interactors, protein identification was performed using the Mascot (v2.3.02) program against the Uniprot human protein database (released Dec 2014) with the default parameters. The false discovery rate was 1%, the protein score was ≥40, and unique peptides were ≥2.
For the identification of exogenous and endogenous RBRP peptide, protein identification was performed using the Mascot (version 2.6.2) program against our generated RBRP protein database with the default parameters. In brief, the following parameters were employed: the enzyme is trypsin; two missed cleavages were allowed; carbamidomethyl (C) was set as fixed modification, whereas acetyl (Protein N-term), deamidated (NQ), and oxidation (M) were considered as variable modifications. Precursor ion mass tolerance and fragment ion mass tolerance were 20 p.p.m. and 0.1 Da, respectively.
RNA affinity purification
Biotin-labeled RNA oligonucleotides containing A or m6A were synthesized by GeneScript (China). RNA affinity purification was performed as previously described17. Briefly, nuclear extracts were prepared from cells using a Nuclear and Cytoplasmic Protein Extraction Kit (Beyotime). Each 1 nmol of biotin-labeled RNA with A or m6A was bound to 100 μL of streptavidin–agarose beads (Sigma) overnight at 4 °C with rotation. RNA-immobilized beads were mixed with the nuclear mixture and incubated at 30 °C for 30 min. These beads were eluted by adding 30 μL of protein loading buffer and boiling for 5 min. The eluted mixtures were then analyzed using western blotting. These A- or m6A-oligo sequences were provided in Supplementary Table 3.
RNA electrophoretic mobility shift assay
RNA electrophoretic mobility shift assay (EMSA) was performed by LightShift RNA EMSA optimization and control kit (Thermo Fisher) following the manufacturer’s instructions and a previous report46. Briefly, IGF2BP1-Flag proteins, WT and G19A-mutated RBRP oncopeptides, were overexpressed and purified from HEK293T cells according to the kit instructions (FLAGIPT1, Sigma) as previously described41. Biotin-labeled m6A-RNA oligos (20 pmol), 6 μg recombined IGF2BP-Flag proteins, together with 2 μg recombined RBRP-Flag oncopeptides or RBRP-Flag G19A mutant oncopeptides were mixed and incubated at room temperature for 30 min. Then, 1 µl of 0.2% glutaraldehyde was added to the mixtures and incubated on ice for 15 min. Then, the RNA-protein/oncopeptide mixtures were separated on 6% TBE (450 mM Tris, 450 mM boric acid, 10 mM EDTA pH 8.3) gel. The gel was transferred to a positively charged nylon transfer membrane (GE Healthcare) and the RNA membrane was crosslinked by UV light. The biotin-labeled m6A-RNA oligos were detected by a chemiluminescent nucleic acid detection module (Thermo Fisher) following the manufacturer’s instructions. These A- or m6A-oligo sequences were provided in Supplementary Table 3.
RIP was performed as previously described with minor modifications6. In brief, cells were crosslinked by UV light and collected by trypsinization. Nuclear extracts were prepared from cells using a Nuclear and Cytoplasmic Protein Extraction Kit (Beyotime). Anti-IGF2BP1 or anti-HA antibodies, or a corresponding control IgG antibody were incubated with protein A/G agarose beads (Santa Cruz) for 4 h at 4 °C, followed by incubation with precleared nuclear extracts in RIP buffer (150 mM KCl, 25 mM Tris (pH 7.4), 5 mM EDTA, 0.5 mM dithiothreitol, 0.5% NP40, 1× protease inhibitor) supplemented with RNase inhibitor at 4 °C overnight. The co-IPed complexes were digested with DNase at 37 °C for 15 min and with proteinase K at 37 °C for 15 min. Input and co-IPed RNAs were extracted by TRIzol (Invitrogen) and determined by qPCR. The related enrichment of RNA in each sample was calculated by normalizing to input as previously described6.
Gene-specific m6A qPCR
C-Myc mRNA m6A levels were determined as previously described with some modifications6. Briefly, total RNA was sheared by an ultrasonicator (Covaris M220). An anti-m6A antibody or a corresponding control IgG antibody were incubated with protein A/G agarose beads (Santa Cruz) for 4 h at 4 °C, followed by incubation with the sheared RNAs in RIP buffer supplemented with RNase inhibitor for 6 h at 4 °C. The immunoprecipitated m6A-methylated RNAs were digested with DNase at 37 °C for 15 min and with proteinase K at 37 °C for 15 min, then extracted by TRIzol (Invitrogen) and determined by qPCR. The related enrichment of m6A in each sample was calculated by normalizing to input.
RNA m6A dot blotting
RNA dot blotting was performed as previously described with minor modifications41. Briefly, total RNAs or RIP-immunoprecipitated RNAs were placed at 55 °C for 15 min to denature in a denaturing buffer (2.2 M formaldehyde, 50% deionized formamide, 0.5× MOPS buffer). RNA was heated at 95 °C for 10 min and cooled on ice for 5 min. RNAs were then spotted onto Amersham Hybond-N+ membranes (GE Healthcare, cat# RPN303B) and crosslinked by UV light. The m6A modifications on RNA were detected with an anti-m6A antibody.
Half-life of mRNA and mRNA stability assay
Cells at 70–80% confluency were treated with 5 µg/ml actinomycin D and collected at the indicated time points. Total RNA was extracted by TRIzol (Invitrogen) and the c-Myc mRNA levels were determined by RT-PCR. The intensity of gel band was measured by ImageJ (v1.8.0) program. The turnover rate and half-life of mRNA were calculated according to previously reported methods6.
Construction of synonymous mutants
Synonymous mutants of IGF2BP1-HA and c-Myc-HA, which are resistant to the anti-IGF2BP1 and c-Myc siRNAs, respectively, were constructed. The anti-IGF2BP1 siRNA-targeted sequence 5′-CTCCGGGAAAGTAGAATT-3′ in WT and GxxGΔ-mutated IGF2BP1-HA plasmids was synonymously mutated to 5′-CTCAGGAAAGGTGGAGTT-3′. The synonymous mutants sIGF2BP1-HA and sIGF2BP1-HA GxxGΔ were generated. The anti-c-Myc siRNA-targeted sequence 5′-GTGCAGCCGTATTTCTACT-3′ in WT and CRDmut-mutated c-Myc-HA plasmids was synonymously mutated to 5′-GTACAACCATACTTTTATT-3′. The synonymous mutants sc-Myc-HA and sc-Myc-HA CRDmut were generated.
Statistical analyses and reproducibility
Two-tailed unpaired Student’s t-test without adjustment was used to compare data between two groups, unless explicitly stated. Mann–Whitney U-test was used to compare clinical data between two groups and has been stated in figure legends. The significance of the growth curves was analyzed using a two-way analysis of variance. The treatment groups were compared with the control, unless stated otherwise. Survival curves were analyzed using the Kaplan–Meier method and compared using the log-rank test. Statistical analyses were performed using Prism 5 or Prism 8 software and the SPSS program. n = 3 independent experiments unless stated. Two independent experiments were performed for immunofluorescence staining assays. One independent experiment was performed for the remaining results. The data are presented as means ± SD, unless indicated otherwise; *p < 0.05, **p < 0.01, ***p < 0.001 and ns, no statistical significance.
Further information on research design is available in the Nature Research Reporting Summary linked to this article.
The mass spectrometry proteomics data for identification of exogenous and endogenous RBRP peptide have been deposited to the ProteomeXchange Consortium (http://proteomecentral.proteomexchange.org) via the iProX47 partner repository with the dataset identifiers PXD016267 and PXD016268. The larger figures for all of the cytology images including the immunofluorescence images (Figs. 1a, b, 2a, 3c, d, 7d, e, and Supplementary Figs. 2a, b, e, 5b, c, e, f, 6c, d, 7c, d, 11c, d) and the uncropped gels and blots (Figs. 1c, 2b, c, 3a, 4a–j, 5a, c, d, f, g, 6c, g, i and Supplementary Figs. 2c, d, 4a, c, 6a, 7a, 8a–d, 9b, c, 10a–e, 11a) are provided as a Source Data file. The raw data for all of our histograms and line charts (Figs. 2e–g, 3b–e, g, 5b, e, h, i, 6a, b, d–f, h, j, k, 7a–e and Supplementary Figs. 2c, 4b, d, 5a–f, 6b–d, 7b–d, 9a, d, 11b–d) are provided as a Source Data file. All other relevant data are available from the corresponding author on reasonable request.
Shi, H., Wei, J. & He, C. Where, when, and how: context-dependent functions of RNA methylation writers, readers, and erasers. Mol. Cell 74, 640–650 (2019).
Deng, X. et al. RNA N(6)-methyladenosine modification in cancers: current status and perspectives. Cell Res. 28, 507–517 (2018).
Liu, J. et al. A METTL3-METTL14 complex mediates mammalian nuclear RNA N6-adenosine methylation. Nat. Chem. Biol. 10, 93–95 (2014).
Han, D. et al. Anti-tumour immunity controlled through mRNA m(6)A methylation and YTHDF1 in dendritic cells. Nature 566, 270–274 (2019).
Xiao, W. et al. Nuclear m(6)A reader YTHDC1 regulates mRNA splicing. Mol. Cell 61, 507–519 (2016).
Huang, H. et al. Recognition of RNA N(6)-methyladenosine by IGF2BP proteins enhances mRNA stability and translation. Nat. Cell Biol. 20, 285–295 (2018).
Alarcon, C. R. et al. HNRNPA2B1 is a mediator of m(6)A-dependent nuclear RNA processing events. Cell 162, 1299–1308 (2015).
Liu, N. et al. N(6)-methyladenosine-dependent RNA structural switches regulate RNA-protein interactions. Nature 518, 560–564 (2015).
Ping, X. L. et al. Mammalian WTAP is a regulatory subunit of the RNA N6-methyladenosine methyltransferase. Cell Res. 24, 177–189 (2014).
Yue, Y. et al. VIRMA mediates preferential m(6)A mRNA methylation in 3′UTR and near stop codon and associates with alternative polyadenylation. Cell Discov. 4, 10 (2018).
Wen, J. et al. Zc3h13 regulates nuclear RNA m(6)A methylation and mouse embryonic stem cell self-renewal. Mol. Cell 69, 1028–1038 e1026 (2018).
Patil, D. P. et al. m(6)A RNA methylation promotes XIST-mediated transcriptional repression. Nature 537, 369–373 (2016).
Huarte, M. The emerging role of lncRNAs in cancer. Nat. Med. 21, 1253–1261 (2015).
Geisler, S. & Coller, J. RNA in unexpected places: long non-coding RNA functions in diverse cellular contexts. Nat. Rev. Mol. Cell Biol. 14, 699–712 (2013).
Ulitsky, I. & Bartel, D. P. lincRNAs: genomics, evolution, and mechanisms. Cell 154, 26–46 (2013).
Sang, L. J. et al. LncRNA CamK-A regulates Ca(2+)-signaling-mediated tumor microenvironment remodeling. Mol. Cell 72, 71–83 e77 (2018).
Huang, J. Z. et al. A peptide encoded by a putative lncRNA HOXB-AS3 suppresses colon cancer growth. Mol. Cell 68, 171–184 e176 (2017).
Wang, Z. et al. lncRNA epigenetic landscape analysis identifies EPIC1 as an oncogenic lncRNA that interacts with MYC and promotes cell-cycle progression in cancer. Cancer Cell 33, 706–720 e709 (2018).
Biswas, J. et al. The structural basis for RNA selectivity by the IMP family of RNA-binding proteins. Nat. Commun. 10, 4440 (2019).
Weidensdorfer, D. et al. Control of c-myc mRNA stability by IGF2BP1-associated cytoplasmic RNPs. RNA 15, 104–115 (2009).
Bell, J. L. et al. Insulin-like growth factor 2 mRNA-binding proteins (IGF2BPs): post-transcriptional drivers of cancer progression? Cell Mol. Life Sci. 70, 2657–2675 (2013).
Fan, X. C. & Steitz, J. A. Overexpression of HuR, a nuclear-cytoplasmic shuttling protein, increases the in vivo stability of ARE-containing mRNAs. EMBO J. 17, 3448–3460 (1998).
Salton, M. et al. Matrin 3 binds and stabilizes mRNA. PLoS ONE 6, e23882 (2011).
Behm-Ansmant, I., Gatfield, D., Rehwinkel, J., Hilgers, V. & Izaurralde, E. A conserved role for cytoplasmic poly(A)-binding protein 1 (PABPC1) in nonsense-mediated mRNA decay. EMBO J. 26, 1591–1601 (2007).
Weng, H. et al. METTL14 inhibits hematopoietic stem/progenitor differentiation and promotes leukemogenesis via mRNA m(6)A modification. Cell Stem Cell 22, 191–205 e199 (2018).
Lin, S., Choe, J., Du, P., Triboulet, R. & Gregory, R. I. The m(6)A methyltransferase METTL3 promotes translation in human cancer cells. Mol. Cell 62, 335–345 (2016).
Li, Z. et al. FTO plays an oncogenic role in acute myeloid leukemia as a N(6)-methyladenosine RNA demethylase. Cancer Cell 31, 127–141 (2017).
Zhang, S. et al. m(6)A demethylase ALKBH5 maintains tumorigenicity of glioblastoma stem-like cells by sustaining FOXM1 expression and cell proliferation program. Cancer Cell 31, 591–606 e596 (2017).
Liu, J. et al. m(6)A mRNA methylation regulates AKT activity to promote the proliferation and tumorigenicity of endometrial cancer. Nat. Cell Biol. 20, 1074–1083 (2018).
Paris, J. et al. Targeting the RNA m(6)A reader YTHDF2 selectively compromises cancer stem cells in acute myeloid leukemia. Cell Stem Cell 25, 137–148 e136 (2019).
Li, B. Q. et al. WT1 associated protein promotes metastasis and chemo-resistance to gemcitabine by stabilizing Fak mRNA in pancreatic cancer. Cancer Lett. 451, 48–57 (2019).
Zhu, D. et al. ZC3H13 suppresses colorectal cancer proliferation and invasion via inactivating Ras-ERK signaling. J. Cell Physiol. 234, 8899–8907 (2019).
Aparicio, L. A., Valladares, M., Blanco, M., Alonso, G. & Figueroa, A. Biological influence of Hakai in cancer: a 10-year review. Cancer Metastasis Rev. 31, 375–386 (2012).
Su, R. et al. R-2HG exhibits anti-tumor activity by targeting FTO/m(6)A/MYC/CEBPA signaling. Cell 172, 90–105 e123 (2018).
David, C. J., Chen, M., Assanah, M., Canoll, P. & Manley, J. L. HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer. Nature 463, 364–368 (2010).
Geuens, T., Bouhy, D. & Timmerman, V. The hnRNP family: insights into their role in health and disease. Hum. Genet. 135, 851–867 (2016).
Polycarpou-Schwarz, M. et al. The cancer-associated microprotein CASIMO1 controls cell proliferation and interacts with squalene epoxidase modulating lipid droplet formation. Oncogene 37, 4750–4768 (2018).
Zhang, M. et al. A peptide encoded by circular form of LINC-PINT suppresses oncogenic transcriptional elongation in glioblastoma. Nat. Commun. 9, 4475 (2018).
Wang, J. et al. ncRNA-encoded peptides or proteins and cancer. Mol. Ther. 27, 1718–1725 (2019).
Zhu, S., Wang, J., He, Y., Meng, N. & Yan, G. R. Peptides/proteins encoded by non-coding RNA: a novel resource bank for drug targets and biomarkers. Front Pharm. 9, 1295 (2018).
Xiao, C. L. et al. N(6)-methyladenine DNA modification in the human genome. Mol. Cell 71, 306–318 e307 (2018).
Xu, S. H. et al. ECD promotes gastric cancer metastasis by blocking E3 ligase ZFP91-mediated hnRNP F ubiquitination and degradation. Cell Death Dis. 9, 479 (2018).
Schagger, H. Tricine-SDS-PAGE. Nat. Protoc. 1, 16–22 (2006).
Xu, S. H. et al. ACK1 promotes gastric cancer epithelial-mesenchymal transition and metastasis through AKT-POU2F1-ECD signalling. J. Pathol. 236, 175–185 (2015).
Huang, J. Z. et al. Down-regulation of TRPS1 stimulates epithelial-mesenchymal transition and metastasis through repression of FOXA1. J. Pathol. 239, 186–196 (2016).
Zhang, C. et al. m(6)A modulates haematopoietic stem and progenitor cell specification. Nature 549, 273–276 (2017).
Ma, J. et al. iProX: an integrated proteome resource. Nucleic Acids Res. 47(D1), D1211–D1217 (2019).
This work was supported by the National Natural Science Foundation of China (81772998, 81672393, and 81802763), the R&D Plan of Guangzhou (201704020115), the Yangcheng Scholars program from the Ministry of Education of Guangzhou (1201561583), Innovative Research Team of Ministry of Education of Guangzhou (1201610015), the R&D Plan of Guangdong (2017A020215096).
The authors declare no competing interests.
Peer review information Nature Communications thanks the anonymous reviewer(s) for their contribution to the peer review of this work. Peer reviewer reports are available.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Zhu, S., Wang, J., Chen, D. et al. An oncopeptide regulates m6A recognition by the m6A reader IGF2BP1 and tumorigenesis. Nat Commun 11, 1685 (2020). https://doi.org/10.1038/s41467-020-15403-9